It has been reported previously that SOCS-1 and SOCS-3 proteins could down-regulate the INF therapeutic efficacy as negative regulators in the IFN signaling pathway in CHC patients, and the overexpression of SOCS-3 protein could be used for the prognosis of CHC patients with INF treatment. This evidence concerns the gene IFNA1 and cryohydrocytosis.